Baxter’s first quarter results received a positive market reaction, reflecting management’s progress on its turnaround strategy despite ongoing operational and margin pressures. Key drivers cited included robust growth in advanced surgery products, steady order volumes in care and connectivity solutions, and initial benefits from efforts to stabilize supply chains and address manufacturing backlogs. CEO Andrew Hider acknowledged the quarter’s challenging comparisons to last year, noting, “We are not satisfied with where our performance stands today, but we have a roadmap in place to improve results and drive shareholder value.” While challenges persist in the pharmaceutical and infusion pump segments, proactive cost controls and targeted innovation initiatives supported the company’s first-quarter performance.
Is now the time to buy BAX? Find out in our full research report (it’s free for active Edge members).
Baxter (BAX) Q1 CY2026 Highlights:
- Revenue: $2.70 billion vs analyst estimates of $2.61 billion (2.9% year-on-year growth, 3.5% beat)
- Adjusted EPS: $0.36 vs analyst estimates of $0.31 (15.9% beat)
- Adjusted EBITDA: $534 million vs analyst estimates of $382.4 million (19.8% margin, 39.6% beat)
- Management reiterated its full-year Adjusted EPS guidance of $1.95 at the midpoint
- Operating Margin: 2.4%, in line with the same quarter last year
- Constant Currency Revenue fell 1% year on year (5% in the same quarter last year)
- Market Capitalization: $8.77 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Baxter’s Q1 Earnings Call
- Robert Marcus (JPMorgan): Asked if the absence of Novum pump returns could create upside to guidance. CFO Anita Zielinski responded that while returns have been immaterial so far, the company prudently continues to factor in this risk for the year.
- David Roman (Goldman Sachs): Queried about the drivers behind back-half margin improvement. Kevin Moran, VP Investor Relations, cited expected seasonal volume increases, cost structure actions, and normalization of cost absorption as key factors.
- Larry Biegelsen (Wells Fargo): Pushed for details on inflation impact and oil exposure. CEO Andrew Hider explained that the divestiture of the Kidney Care business reduced oil dependency, and proactive supply chain measures are in place to manage broader inflation.
- Matthew Miksic (Barclays): Asked about microchip supply chain risks. Hider stated no material disruptions have occurred but emphasized ongoing dual sourcing and disciplined forecasting to mitigate future risks.
- Joanne Wuensch (Citi): Requested updates on the CFO search and recovery in injectables. Hider confirmed the search is ongoing, with strong interest, and outlined ongoing efforts to resolve supply constraints in the injectables business.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) the pace and commercial impact of new product launches in Connected Care and Advanced Surgery, (2) evidence of margin recovery from cost structure initiatives and operational improvements, and (3) resolution of supply chain bottlenecks, particularly in the injectables and infusion pump segments. Progress on these fronts, along with updates on the permanent CFO search and further adoption of GPS initiatives, will be key milestones to watch.
Baxter currently trades at $16.97, in line with $16.90 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
